The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents

Completed

• Conditions: Sepsis
• Interventions: Drug: Linezolid or Vancomycin

• Registration Number: NCT00811980
• Lead Sponsor: University of Utah

Brief Summary

We will determine if linezolid inhibits cellular activation and production of pro-inflammatory cytokines, providing mechanistic rationale for its clinical efficacy and the justification for further investigations in S. Aureus sepsis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-12-17
• Study First Submitted QC: 2008-12-18
• Study First Posted: 2008-12-19
• Study Start: 2009-01
• Primary Completion: 2010-06
• Study Completion: 2010-06
• Status Verified: 2011-11
• Last Update Submitted: 2011-11-23
• Last Update Posted: 2011-11-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Healthy, taking no medications, and not recently hospitalized

Exclusion Criteria

• Infection (active)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Heathy Subjects	Linezolid or Vancomycin	-

Primary Outcome Measures

Name	Time	Method
IL-6	12 Months	Measurement of IL-6 release in response to MRSA.

Secondary Outcome Measures

Name	Time	Method
MCP-1	12 Months	Measurement of MCP-1 release in response to MRSA.